Get the Stockscreener App
2.72
1.12%
0.03
After Hours:
2.72
Scinai Immunotherapeutics Ltd Adr stock is traded at $2.72, with a volume of 7,643.
It is up +1.12% in the last 24 hours and up +6.67% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
See More
Previous Close:
$2.69
Open:
$2.7196
24h Volume:
7,643
Relative Volume:
0.59
Market Cap:
$10.88B
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-0.5231
EPS:
-5.2
Net Cash Flow:
$-9.42M
1W Performance:
-1.45%
1M Performance:
+6.67%
6M Performance:
-20.93%
1Y Performance:
-24.44%
1-Day Range:
$2.7196
$2.86
1-Week Range:
$2.68
$2.8928
52-Week Range:
$1.90
$8.92
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
2.72 | 2.76M | 0 | -9.29M | -9.42M | -5.20 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports $4.8M Net Gain in 2024, Driven by Loan-to-Equity Conversion - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders - Barchart.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters $10M Standby Equity Purchase Agreement - Barchart
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Evaluating the Annual Growth - The News Heater
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Strategic Board Appointment - Barchart
Scinai Immunotherapeutics (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board - Barchart
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports Nine-Month Financial Results - Barchart
Scinai Immunotherapeutics (NASDAQ: SCNI) to Spotlight I&I Pipeline, CDMO Services at BIO-Europe 2024 - Barchart
Bayerische Motoren Werke ADR (OP: BMWYY - FinancialContent
Scinai reports Q1 results, progresses in pipeline By Investing.com - Investing.com South Africa
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):